Chinese Biotech Strategies: The Pros & Cons of In-Licensing
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios…
See our Cookie Privacy Policy Here